argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
704.07
-3.89 (-0.55%)
At close: Aug 28, 2025, 4:00 PM
704.00
-0.07 (-0.01%)
After-hours: Aug 28, 2025, 5:45 PM EDT
argenx SE Revenue
argenx SE had revenue of $967.19M in the quarter ending June 30, 2025, with 97.62% growth. This brings the company's revenue in the last twelve months to $3.12B, up 88.04% year-over-year. In the year 2024, argenx SE had annual revenue of $2.25B with 77.22% growth.
Revenue (ttm)
$3.12B
Revenue Growth
+88.04%
P/S Ratio
13.78
Revenue / Employee
$1,951,733
Employees
1,599
Market Cap
43.01B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.25B | 979.61M | 77.22% |
Dec 31, 2023 | 1.27B | 827.58M | 187.66% |
Dec 31, 2022 | 441.01M | -87.25M | -16.52% |
Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ARGX News
- 1 day ago - argenx to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 days ago - Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win - Benzinga
- 4 days ago - argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG - GlobeNewsWire
- 10 days ago - argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025 - GlobeNewsWire
- 16 days ago - argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis - GlobeNewsWire
- 21 days ago - Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts - Seeking Alpha
- 4 weeks ago - argenx SE (ARGX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update - GlobeNewsWire